AstraZeneca’s MEK Inhibitor Boosts PFS, But Misses Overall Survival Endpoint In Lung Trial

This article was originally published in Pharmaceutical Approvals Monthly

20 Jun 2012
News

Emily Hayes @emilykatehayes emily.hayes@informa.com

Executive Summary

MEK inhibitor selumetinib improves progression-free survival in KRAS mutation-positive metastatic non-small cell lung cancer, hitting secondary endpoints. But the drug missed the overall survival primary endpoint.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Subjects
Clinical Trials

Related Companies

Related Deals

Array BioPharma, AstraZeneca sign cancer deal

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Clinical Trials

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS005105

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS005105

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

AstraZeneca’s MEK Inhibitor Boosts PFS, But Misses Overall Survival Endpoint In Lung Trial

News

Executive Summary

Related Content

AstraZeneca Oncology Focused On Combinations, But Differentiation Will Be Key

Over A Decade In The Making, MEK Inhibitors Break Through In Melanoma

Topics

Related Companies

Related Deals

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert